James M. Inhofe sold Crispr Therapeutics AG (NASDAQ: CRSP)
James M. Inhofe (R-OK), a U.S. Senator, has disclosed 4 trades in Crispr Therapeutics AG (CRSP) since 2017, 1 purchase and 3 sales, worth an estimated $148K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: James M. Inhofe sold $50,001 - $100,000 of Crispr Therapeutics AG (NASDAQ: CRSP) on December 22, 2020. Since that trade, CRSP is down -70.33% against the S&P 500 up +119.92%, an outperformance of -190.25%.
Across these filings, James M. Inhofe has been a net seller of CRSP (a buy-to-sell ratio of 0.33). The most recent disclosed CRSP transaction shown was dated January 5, 2021. Each row in the table below links to that trade and its post-trade performance versus the market.
Data updated
James M. Inhofe's CRSP trades vs the price
CRSP is down -70.33% since James M. Inhofe sold on December 22, 2020, versus +119.92% for the S&P 500.
Performance since this trade
All James M. Inhofe CRSP trades
| Traded | Type | Size | Return | Est. profit | |
|---|---|---|---|---|---|
| January 5, 2021 | SELL | $160.62 | -68.58% | — | |
| December 22, 2020 | SELL | $170.08 | -70.33% | — | |
| June 19, 2018 | SELL | $62.06 | -18.69% | — | |
| October 19, 2017 | BUY | $18.97 | +166.00% | +$54K |
Estimated profit is shown for buys only, marked to the latest close. It is an estimate and does not net later sells, taxes, or fees.
James M. Inhofe & CRSP trading FAQ
Is it legal for James M. Inhofe to trade Crispr Therapeutics AG (CRSP) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Crispr Therapeutics AG (CRSP), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did James M. Inhofe sell CRSP?
James M. Inhofe disclosed a sale of $50,001 - $100,000 of Crispr Therapeutics AG (CRSP) on December 22, 2020, according to public STOCK Act filings.
How has CRSP performed since James M. Inhofe's trade?
Since James M. Inhofe sold CRSP on December 22, 2020, the stock is down -70.33%, versus +119.92% for the S&P 500 over the same period, an outperformance of -190.25%.
How many times has James M. Inhofe traded CRSP?
James M. Inhofe has disclosed 4 CRSP trades since 2017 (1 purchase and 3 sales). Every disclosed trade is listed on this page.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional CRSP trades?
Quantellect tracks every disclosed congressional trade in Crispr Therapeutics AG (CRSP) on the Crispr Therapeutics AG congressional trading page, which aggregates filings across all members of Congress.
James M. Inhofe's CRSP tradesAll congressional filings for Crispr Therapeutics AGJames M. Inhofe's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.